http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs
-
Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs
-
Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs
-
OSE Immunotherapeutics Reports on First-Half 2017 Financial Results and Provides Update on Clinical Advances of Its Product Portfolio
-
OSE Immunotherapeutics Partners with Oncology Physician Network GERCOR to Conduct a Combination Phase 2 Trial of Tedopi® for Pancreatic Cancer
-
OSE Immunotherapeutics Announces Presentation at The 19th Annual Rodman & Renshaw Global Investment Conference In New York City, September 10-12, 2017
-
OSE Immunotherapeutics Announces Presentation at The 19th Annual Rodman & Renshaw Global Investment Conference in New York City, September 10-12, 2017
-
OSE Immunotherapeutics Receives €9.2 million Grant from Bpifrance “Invest in the Future Program” for Development of New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM)
-
OSE Immunotherapeutics Receives €9.2 Million Grant From Bpifrance “Invest in the Future Program” for Development of New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM)
-
OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial of Tedopi® in Advanced Lung Cancer
-
OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial of Tedopi® in Advanced Lung Cancer
-
OSE Immunotherapeutics Receives Payment of €2.6 Million from Bpifrance After Completion of a New Key Milestone for its Product OSE-127
-
OSE Immunotherapeutics Receives Payment of €2.6 Million from Bpifrance After Completion of a New Key Milestone for its Product OSE-127
-
OSE Immunotherapeutics Presents Positive Preclinical Results and Human Ex Vivo Data for OSE-127 (Effi-7) to Support Next Clinical Applications in Inflammatory Bowel Diseases
-
OSE Immunotherapeutics Presents Positive Preclinical Results and Human Ex Vivo Data for OSE-127 (Effi-7) to Support Next Clinical Applications in Inflammatory Bowel Diseases at the Federation of Clin
-
OSE Immunotherapeutics Announces Results of 2017 Annual Meeting of Shareholders
-
OSE Immunotherapeutics Announces Results of 2017 Annual Meeting of Shareholders
-
Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE's Interleukin Receptor 7 Antagonist
-
Selexis SA And OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist
-
OSE Immunotherapeutics Strengthens R&D Team with Appointment of Two Senior Talented Immunologists
-
OSE Immunotherapeutics Strengthens R&D Team with Appointment of Two Senior Talented Immunologists
-
OSE Immunotherapeutics to Present at Annual Sachs Immuno-Oncology: BD&L and Investment Forum
-
OSE Immunotherapeutics to Present at Annual Sachs Immuno-Oncology: BD&L and Investment Forum
-
OSE Immunotherapeutics Presents New Data on Anti-SIRPa (Effi-DEM), the Checkpoint Inhibitor blocking Pro-Tumor and Suppressor Myeloid Cells at “Advances in Immuno-Oncology Congress,” London, May 1
-
OSE Immunotherapeutics Presents New Data on Anti-SIRPa (Effi-DEM), the Checkpoint Inhibitor blocking Pro-Tumor and Suppressor Myeloid Cells at “Advances in Immuno-Oncology Congress”, London, May 1
-
OSE Immunotherapeutics Presented New Data at AACR* Annual Meeting 2017 on OSE-172 (Effi-DEM), Company’s Checkpoint Inhibitor Blocking Suppressive Myeloid Cells and Inducing Antitumoral Potent T Me
-
OSE Immunotherapeutics SA: 2016 Results: Significant Milestones, First Profit, More Growth to Come
-
2016 Results: Significant Milestones, First Profit, More Growth to Come
-
OSE Immunotherapeutics New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM) at the 24th Molecular Med TRI-CON 2017 Meeting
-
OSE Immunotherapeutics New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM) at the 24Th Molecular Med TRI-CON 2017 Meeting
-
OSE Immunotherapeutics to Present Corporate Overview at Upcoming BIO CEO & Investor Conference New York February 13-14, 2017
-
OSE Immunotherapeutics Announces That the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Pivotal Phase 3 Clinical Trial of Tedopi® in Non-Small Cell Lung Cancer
-
OSE Immunotherapeutics to Present at Biotech Showcase™ 2017 Conference
-
OSE Immunotherapeutics Appoints Dr. Frédérique Corallo, as Chief Medical Officer, Immunology
-
Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases
-
Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases
-
OSE Immunotherapeutics Awarded First Prize and "Listed Company" Prize as Part of 2016 Deloitte In Extenso Technology Fast 50 Ouest
-
OSE Immunotherapeutics to Present at 2016 MedStart Up Days
-
OSE Immunotherapeutics to Present the Preclinical Data of Its New Checkpoint Inhibitor Effi-DEM on SIRP-α/CD47 Strategic Pathway at the 2016 Immune Checkpoint Inhibitors Conference
-
OSE Pharma SA: Availability of Preparatory Documents for the Combined General Meeting of May 31, 2016
-
OSE Pharma and Effimune Announce the Signing of the Merger Treaty to Create OSE Immunotherapeutics
-
OSE Pharma: Fifth Country Opens Recruitment in the Global Pivotal Phase 3 Trial of the Immunotherapy Tedopi® with Initiation in Hungary
-
OSE Pharma to Join Workshop
-
OSE Pharma to Attend the Small & Midcap Event in Paris on 11 & 12 April, 2016
-
OSE Pharma: 2015 Annual Results in Line with Forecasts, and Significant Clinical Advances
-
OSE Pharma and Effimune Announce Proposed Merger to Create Significant Immunotherapy Player
-
OSE Pharma SA: First patients enrolled and dosed in the pivotal trial of Phase 3 of the immunotherapy Tedopi® for advanced non-small cell lung cancer
-
OSE Pharma Announces U.S. Initiation of Atalante 1, the Company’s Global, Pivotal Phase 3 Trial for Tedopi® Immunotherapy in Non-Small Cell Lung Cancer
-
OSE Pharma Announces Initiation of Its Pivotal Phase 3 Trial of Tedopi® in Non-Small Cell Lung Cancer
-
OSE Pharma Announces Its Events for Q1 2016
